Asset Details
Do you wish to reserve the book?
Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10
Do you wish to request the book?
Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10
2016
Overview
Acute graft-versus-host disease (aGVHD) remains a major complication following allogeneic hematopoietic cell transplantation, limiting the success of this therapy. We previously reported that interleukin-22 (IL-22) participates to aGVHD development, but the underlying mechanisms of its contribution remain poorly understood. In this study, we analyzed the mechanism of the pathological function of IL-22 in intestinal aGVHD. Ex-vivo colon culture experiments indicated that IL-22 was able to induce Th1-like inflammation via signal transducer and activator of transcription factor-1 (STAT1) and CXCL10 induction in the presence of type I interferon (IFN). To evaluate a potential synergy between IL-22 and type I IFN in aGVHD, we transplanted recipient mice, either wild-type (WT) or type I IFN receptor deficient (IFNAR−/−), with bone marrow cells and WT or IL-22 deficient (IL-22−/−) T cells. We observed a decreased GVHD severity in IFNAR−/− recipient of IL-22−/− T cells, which was associated with a lower level of STAT1 activation and reduced CXCL10 expression in the large intestine. Finally, immunohistochemistry staining of STAT1 performed on gastrointestinal biopsies of 20 transplanted patients showed exacerbated STAT1 activation in gastrointestinal tissues of patients with aGVHD as compared with those without aGVHD. Thus, interfering with both IL-22 and type I IFN signaling may provide a novel approach to limit aGVHD.
Publisher
Elsevier Inc,Nature Publishing Group US,Elsevier Limited,Nature Pub. Group
Subject
/ Animals
/ Biomedical and Life Sciences
/ Chemokine CXCL10 - immunology
/ Graft vs Host Disease - genetics
/ Graft vs Host Disease - immunology
/ Graft vs Host Disease - pathology
/ Hematologic Neoplasms - genetics
/ Hematologic Neoplasms - immunology
/ Hematologic Neoplasms - pathology
/ Hematologic Neoplasms - therapy
/ Humans
/ Interferon Type I - genetics
/ Interferon Type I - immunology
/ Intestinal Mucosa - immunology
/ Intestinal Mucosa - pathology
/ Intestine, Large - immunology
/ Intestine, Large - pathology
/ Mice
/ Receptor, Interferon alpha-beta - deficiency
/ Receptor, Interferon alpha-beta - genetics
/ Receptor, Interferon alpha-beta - immunology
/ STAT1 Transcription Factor - genetics
